Personalized Management Strategy in Patients with Acute Myocardial Infarction

Acute myocardial infarction (AMI) is a multifactorial condition characterized by high morbidity and mortality, where inflammation and immune activation play a central role in myocardial injury and remodeling. In recent years, the concept of personalized medicine has emerged as a promising strategy to improve outcomes by tailoring therapy to individual biological profiles. Objective: To evaluate the clinical efficacy of a personalized management approach in AMI patients based on immunological and metabolic markers, comorbidity profiles, and cardiovascular remodeling indicators. Methods: A total of 120 patients with AMI were divided into two groups: the control group received standard ESC-based therapy, and the experimental group underwent personalized treatment that included cytokine-guided immunocorrection (targeting IL-6, IL-17A, TNF-α), metabolic and antioxidant support, and optimized use of β-blockers and ACE inhibitors. Clinical, echocardiographic, and biochemical parameters were analyzed on admission, day 5, and day 30. Results: Patients receiving personalized therapy demonstrated a faster reduction in inflammatory markers (IL-6 ↓47%, IL-17A ↓41%), improved left ventricular ejection fraction (LVEF ↑9.3 ± 1.2%), and a 32% decrease in early post-infarction complications. Significant correlations were identified between IL-17A and LVEF (r = –0.56, p < 0.001), and between IL-6 and troponin I (r = +0.48, p < 0.01), confirming the pathogenetic role of immune activation in post-infarction remodeling. Conclusion: The integration of immunological, metabolic, and clinical parameters into a personalized management algorithm enhances the effectiveness of AMI treatment, reduces inflammatory activity, and improves cardiac function and prognosis. These findings support the introduction of individualized therapeutic strategies into contemporary cardiology practice.